Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers.
about
HIV-1 superinfection in women broadens and strengthens the neutralizing antibody responseDNA immunization as a technology platform for monoclonal antibody inductionHIV-1 neutralizing antibodies: understanding nature's pathwaysSynthetic DNA vaccine strategies against persistent viral infectionsImmunogenicity and Protective Efficacy of Brugia malayi Heavy Chain Myosin as Homologous DNA, Protein and Heterologous DNA/Protein Prime Boost Vaccine in Rodent ModelSang Froid in a time of trouble: is a vaccine against HIV possible?Influenza H5 hemagglutinin DNA primes the antibody response elicited by the live attenuated influenza A/Vietnam/1203/2004 vaccine in ferretsIn vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteersHuman immunodeficiency virus vaccine trialsHIV-1 vaccine development after STEP.Novel directions in HIV-1 vaccines revealed from clinical trialsDNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice.Antigen engineering can play a critical role in the protective immunity elicited by Yersinia pestis DNA vaccines.Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developmentsProfiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies.Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.Potency, efficacy and durability of DNA/DNA, DNA/protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c mice.HIVIS-DNA or HIVISopt-DNA priming followed by CMDR vaccinia-based boosts induce both humoral and cellular murine immune responses to HIV.Characterization and immunogenicity of a novel mosaic M HIV-1 gp140 trimerInfection by discordant strains of HIV-1 markedly enhances the neutralizing antibody response against heterologous virusNew approaches to design HIV-1 T-cell vaccinesA versatile vector for the production of pseudotyped viruses expressing gp120 antigens from different clades of primary HIV-1 isolates.Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulationsSequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodiesVaccination of mice using the West Nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge.Clinical applications of DNA vaccines: current progress.Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion.DNA-Launched Alphavirus Replicons Encoding a Fusion of Mycobacterial Antigens Acr and Ag85B Are Immunogenic and Protective in a Murine Model of TB Infection.Pilot Study on the Use of DNA Priming Immunization to Enhance Y. pestis LcrV-Specific B Cell Responses Elicited by a Recombinant LcrV Protein Vaccine.Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1.Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants.Strategies for eliciting HIV-1 inhibitory antibodiesOptimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated diseasePilot study on the immunogenicity of paired Env immunogens from mother-to-child transmitted HIV-1 isolates.Designing tomorrow's vaccines.CryJ-LAMP DNA Vaccines for Japanese Red Cedar Allergy Induce Robust Th1-Type Immune Responses in Murine ModelReduced MyD88 dependency of ISCOMATRIX™ adjuvant in a DNA prime-protein boost HIV vaccine.Technical transformation of biodefense vaccines.T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces.Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001
P2860
Q21090490-F72E06F1-F606-492D-93E5-8461F2E61C1CQ26751432-3652C4A9-20F1-47AC-86E0-579DAA155BDAQ27000480-BD290BCE-352A-4656-97DC-B40C8CC3B787Q27016078-FA07CB0C-0CD6-4859-972E-CA0FF5F968D7Q27345320-E17726E0-7F5E-4E99-AD9E-D2DEEBC57CE7Q27487961-836A2D41-0BA5-4C60-AD37-C6C8F0AF2795Q28742787-66390719-ABCC-4137-B174-C44DDCC98B75Q28744555-00954B7E-1551-4401-97D6-5C564341B921Q30424366-F144C333-BC2E-4D00-86F2-012C4B205A15Q33642318-E2FC8E59-C742-4076-B5A2-6107ACDF5D11Q33645528-C079F633-79FB-417F-8FE1-A2CDEEEF2510Q33647708-EF5E5618-E71F-4B2A-A0B0-CEFE7ABB4349Q33698142-3D8066AC-2F46-4822-9B87-829DA1504210Q33713435-7246EB41-B6EE-4A1E-915E-9754EFD720DFQ33749827-3A05D1A9-8894-4D2F-AD3E-5CD3ACF675C7Q33759392-E29ACA92-E96A-4037-9B77-58A9D43A99CDQ33818084-5687C262-AC6E-4D06-A345-746D881ACD00Q33869332-D1A486BA-CBB6-436E-8A2D-23D4B121CE4AQ34059543-CE47AF60-8EDC-4A08-B4E2-CDA2B90FDC72Q34120140-537C6557-9E48-46AA-B147-D5D297C179B1Q34274849-4D030995-0BC3-4FA0-8245-A14D90721945Q34444535-141285DD-F281-4EF2-BCEF-ED349090E11AQ34641666-5F3369A8-911C-4AED-9AEF-958907077BBDQ34982715-15D31C88-6EB4-4911-963F-44A6C2FBF3CEQ35087579-4654BDC7-E9D3-462D-AA8C-C8FCCA6DFC3BQ35452312-F6DFBE5D-B38F-4276-B574-5E3F8FD3DEBCQ35558828-3BE3741D-858F-4A4B-8A91-C2BE7608A7A0Q35758746-EE180735-639F-4C76-871A-606F7EAE9AC1Q35826610-95BE38B8-0F19-4F7C-A999-1AFF07A0A3F6Q36114395-A0A4FC6B-2C13-41B1-895E-2DBD9823EC44Q36119504-0F8E6DAC-D57B-450D-A4B5-A53E7C471498Q36452155-682A92CE-2FB8-4825-8407-84F758DEC650Q36616505-C37CEFEE-DEA6-434C-9F16-5703F89BCB51Q36694846-25D56822-0AD2-4D6A-B186-4C294EA4BA28Q36730618-D9C205DA-F204-4832-BC3D-C72B5DDA80B8Q36901422-863E1A56-2FD0-4DFA-A942-9061262549B5Q36977750-24D95FE7-822B-4CAF-AD1A-452DADC15616Q37058898-FAA43836-955A-45D6-991A-DBFD937F454CQ37333743-A8D99423-D577-4A00-AF05-D28209881AC0Q37409262-3811E818-63AE-4182-B7B7-B74AAF7818CF
P2860
Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Cross-subtype antibody and cel ...... e in healthy human volunteers.
@en
Cross-subtype antibody and cel ...... e in healthy human volunteers.
@nl
type
label
Cross-subtype antibody and cel ...... e in healthy human volunteers.
@en
Cross-subtype antibody and cel ...... e in healthy human volunteers.
@nl
prefLabel
Cross-subtype antibody and cel ...... e in healthy human volunteers.
@en
Cross-subtype antibody and cel ...... e in healthy human volunteers.
@nl
P2093
P2860
P1433
P1476
Cross-subtype antibody and cel ...... e in healthy human volunteers.
@en
P2093
Alan L Rothman
Francis A Ennis
James Arthos
Jeffrey S Kennedy
John Lawrence
Phillip Markham
Ranajit Pal
Scott Coley
Sharone Green
P2860
P304
P356
10.1016/J.VACCINE.2007.12.060
P407
P577
2008-07-01T00:00:00Z